Published in Health Business Week, September 26th, 2008
Liquiritigenin is one of the active compounds of MF101, Bionovo's drug candidate for the treatment of menopausal hot flashes, currently poised to start Phase 3 clinical testing.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.